Peter Hillmen P, Badoux X, Delgado J, et al. Safety results of terminated phase 2 study of idelalisib plus rituximab in treatment naïve chronic lymphocytic leukemia (CLL) with del(17p). EHA 2017, abstract S465.
Lagere ADAMTS13-activiteit tijdens TTP-remissie geassocieerd met CVA
nov 2019 | Benigne hematologie